The Prognosis of MGMT Promoter Methylation in Glioblastoma Patients of Different Race: A Meta-analysis

被引:14
|
作者
Yang, Haiyu [1 ]
Wei, Danping [1 ]
Yang, Kunxian [2 ]
Tang, Wenru [1 ]
Luo, Ying [1 ]
Zhang, Jihong [1 ,3 ]
机构
[1] Kunming Univ Sci & Technol, Lab Mol Genet Aging & Tumor, Fac Med, Kunming 650500, Yunnan, Peoples R China
[2] First Peoples Hosp Yunnan Prov, Oncol Dept Breast & Thyroid Surg, Kunming 653200, Yunnan, Peoples R China
[3] Kunming Univ Sci & Technol, Lab Mol Genet Aging & Tumor, Fac Life Sci & Technol, Kunming 650500, Yunnan, Peoples R China
基金
美国国家科学基金会;
关键词
Meta-analysis; Glioblastoma; Promoter methylation; Prognostic factors; O-6 -Methylguanine-DNA methyltransferase (MGMT); NEWLY-DIAGNOSED GLIOBLASTOMA; O-6-METHYLGUANINE DNA-METHYLTRANSFERASE; ELDERLY-PATIENTS; IMMUNOHISTOCHEMICAL EXPRESSION; ADJUVANT TEMOZOLOMIDE; GENE; RADIOTHERAPY; CONCOMITANT; SURVIVAL; RESISTANCE;
D O I
10.1007/s11064-014-1435-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
O-6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair gene. Epigenetic silencing of the MGMT promoter methylation compromises DNA repair and has been associated with longer survival in patients with glioblastoma (GBM) who receive alkylating agents. But the prognostic of MGMT promoter methylation in GBM patients of different race is still ambiguous. Based on an univariate or multivariate analysis between different race (Caucasian and Asian), a meta-analysis of the effects of MGMT promoter methylation on both progression-free survival (PFS) and overall survival (OS) among GBM patients was conducted. A total of 6,309 patients from 50 studies were involved in the analysis. Random effect models were applied to estimate the pooled hazard ratio (HR) with 95 % confidence intervals (CIs) for GBM patients of different race prognosis, the Chi square-based Q test was used to test heterogeneity. Begg's (funnel plot method) and Egger's linear regression tests were adopted to check publication bias (a bias with regard to what is likely to be published, among what is available to be published). The HR value estimated for OS was 0.524 (95 % CI 0.428-0.640) by univariate analysis and 0.427 (95 % CI 0.355-0.513) by multivariate analysis in Caucasian. The HR value estimated for OS was 0.892 (95 % CI 0.469-1.698) by univariate analysis and 0.562 (95 % CI 0.394-0.804) by multivariate analysis in Asian. The HR value estimated for PFS was 0.526 (95 % CI 0.372-0.743) by univariate analysis and 0.437 (95 % CI 0.356-0.537) by multivariate analysis in Caucasian. The HR value estimated for PFS was 0.132 (95 % CI 0.006-3.027) by multivariate analysis in Asian. This data revealed that GBM patients with MGMT promoter methylation had longer OS and PFS by univariate or multivariate analysis in Caucasian regardless of therapeutic intervention. However, GBM patients with MGMT promoter methylation only had longer OS by multivariate analysis in Asian.
引用
收藏
页码:2277 / 2287
页数:11
相关论文
共 50 条
  • [1] The Prognosis of MGMT Promoter Methylation in Glioblastoma Patients of Different Race: A Meta-analysis
    Haiyu Yang
    Danping Wei
    Kunxian Yang
    Wenru Tang
    Ying Luo
    Jihong Zhang
    Neurochemical Research, 2014, 39 : 2277 - 2287
  • [2] MGMT Promoter Methylation and Glioblastoma Prognosis: A Systematic Review and Meta-analysis
    Chen, Yang
    Hu, Fulan
    Zhou, Yiheng
    Chen, Wangyang
    Shao, Hongying
    Zhang, Ying
    ARCHIVES OF MEDICAL RESEARCH, 2013, 44 (04) : 281 - 290
  • [3] Prognosis value of MGMT promoter methylation for patients with lung cancer: a meta-analysis
    Chen, Chao
    Hua, Haiqing
    Han, Chenglong
    Cheng, Yuan
    Cheng, Yin
    Wang, Zhen
    Bao, Jutao
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2015, 8 (09): : 11560 - 11564
  • [4] The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis
    Zhang, Kui
    Wang, Xiao-qin
    Zhou, Bin
    Zhang, Lin
    FAMILIAL CANCER, 2013, 12 (03) : 449 - 458
  • [5] The prognostic value of MGMT promoter methylation in Glioblastoma multiforme: a meta-analysis
    Kui Zhang
    Xiao-qin Wang
    Bin Zhou
    Lin Zhang
    Familial Cancer, 2013, 12 : 449 - 458
  • [6] The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in Elderly Glioblastoma Patients: A Meta-Analysis
    Yin, An-an
    Zhang, Lu-hua
    Cheng, Jin-xiang
    Dong, Yu
    Liu, Bo-lin
    Han, Ning
    Zhang, Xiang
    PLOS ONE, 2014, 9 (01):
  • [7] The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials
    Binabaj, Maryam Moradi
    Bahrami, Afsane
    ShahidSales, Soodabeh
    Joodi, Marjan
    Mashhad, Mona Joudi
    Hassanian, Seyed Mahdi
    Anvari, Kazem
    Avan, Amir
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (01) : 378 - 386
  • [8] Aberrant Methylation of MGMT Promoter in HNSCC: A Meta-Analysis
    Cai, Fucheng
    Xiao, Xiyue
    Niu, Xun
    Shi, Hao
    Zhong, Yi
    PLOS ONE, 2016, 11 (09):
  • [9] MGMT promoter methylation in Peruvian patients with glioblastoma
    Belmar-Lopez, Carolina
    Castaneda, Carlos A.
    Castillo, Miluska
    Garcia-Corrochano, Pamela
    Orrego, Enrique
    Melendez, Barbara
    Casavilca, Sandro
    Flores, Claudio
    Orrego, Enrique
    ECANCERMEDICALSCIENCE, 2018, 12
  • [10] MGMT promoter methylation in glioblastoma
    Santosh, Vani
    Sravya, P.
    NEUROLOGY INDIA, 2018, 66 (04) : 1115 - 1116